Eli Lilly and Company announced on Friday that Canada had granted authorization for the use of bamlanivimab (LY-CoV-555) as a treatment option for adults and pediatric patients 12 years of age or older with mild to moderate Covid-19 who weigh at least 40 kg and at high risk of progressing to severe Covid-19 illness or hospitalization. The authorization, the second authorization worldwide for bamlanivimab, was granted under the Interim Order Respecting the Importation, Sale, and Advertising of Drugs for Use in Relation to Covid-19. This comes following impressive results from BLAZE-1, a randomized, double-blind placebo-controlled phase 2 study in patients with recently diagnosed mild to moderate Covid-19.
“This authorization in Canada furthers our goal of making bamlanivimab available to patients who need it around the world and is evidence of strong collaboration between industry and governments to get Covid-19 medicines to people as quickly as possible," disclosed David A. Ricks, Lilly's chairman, and CEO. "We are proud that this treatment, which was developed in partnership with the Canadian biotech company AbCellera, will soon be available to help people in Canada combat this pandemic."
In Blaze-1, patients placed on bamlanivimab treatment showed decreased viral load and rates of symptoms and hospitalization. In Blaze-1, frequency and kinds of diverse events were identical between bamlanivimab and placebo, with the majority being mild to moderate in severity. Infusion reactions and other allergic hypersensitivity events have been highlighted.
“As a Canadian company, we are proud to contribute to the global fight against Covid-19 and hope our efforts will help people in Canada and around the world in the face of this medical emergency,” said Carl Hansen, Ph.D., CEO of AbCellera. “We applaud Lilly for bringing bamlanivimab to patients at record speed and its commitment to ensuring treatment access for patients with high unmet needs, no matter where they live."